Parkinson's disease: prospects for improved drug therapy
作者： Jim J Hagan , Derek N Middlemiss , Paul C Sharpe , George H Poste
DOI: 10.1016/S0165-6147(97)01050-X
关键词:
摘要: Abstract l-Dopa has long been the mainstay of therapy for Parkinson's disease but its long-term shortcomings, principally uncoordinated, spasmodic or irregular movements (dyskinesias) and fluctuating control motor symptoms (on/off fluctuations), are well documented. The postulated neuroprotective properties l-deprenyl, often used as an adjunct to l-dopa, under scrutiny doubts have also raised regarding safety. Alternative therapeutic approaches clearly needed. In this review, Jim Hagan, Derek Middlemiss, Paul Sharpe George Poste outline some new treatment, with emphasis on novel, selective dopamine receptor agonists. addition, is commonly thought be caused by neurotoxic effects unidentified agent recent data indicate a greater genetic component than previously recognized. Developments in genetics may provide key next generation therapeutics.
elsevier.com
sci-hub.se 参考文章(81)
Paul J. Bédard, Baltazar Gomez Mancilla, Pierre Blanchette, Céline Gagnon, Thérèse Di Paolo, Levodopa-induced dyskinesia: facts and fancy. What does the MPTP monkey model tell us? Canadian Journal of Neurological Sciences. ,vol. 19, pp. 134- 137 ,(1992) , 10.1017/S0317167100041500
A J Lees, J Head, Y Ben-Shlomo, Effect of adding selegiline to levodopa in early, mild Parkinson's disease BMJ. ,vol. 312, pp. 704- 705 ,(1996) , 10.1136/BMJ.312.7032.704B
The basal ganglia III Springer New York. ,(1991) , 10.1007/978-1-4684-5871-8
Basic, clinical, and therapeutic aspects of Alzheimer's and Parkinson's diseases Springer New York. ,(1990) , 10.1007/978-1-4684-5844-2
M Gerlach, H Vogt, P Riederer, Effect of adding selegeline to levodopa in early, mild Parkinson's disease. "On treatment" rather than intention to treat analysis should have been used. BMJ. ,vol. 312, pp. 704- 705 ,(1996)
Takao Nakanishi, Makoto Iwata, Ikuo Goto, Ichiro Kanazawa, Hisayuki Kowa, Tohru Mannen, Yoshikuni Mizuno, Hiroshi Nishitani, Norio Ogawa, Akira Takahashi, Kunio Tashiroi, Hideo Tohgi, Nobuo Yanagisawa, Nation-wide collaborative study on the long-term effects of bromocriptine in the treatment of Parkinsonian patients : final report European Neurology. ,vol. 32, pp. 9- 22 ,(1992) , 10.1159/000116865
André Barbeau, L-Dopa Therapy in Parkinson's Disease: A Critical Review of Nine Years' Experience Canadian Medical Association Journal. ,vol. 101, pp. 59- 68 ,(1969)
J. Langston, P Ballard, J. Tetrud, I Irwin, Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis Science. ,vol. 219, pp. 979- 980 ,(1983) , 10.1126/SCIENCE.6823561
Judit Mally, Attila B. Kovacs, T.W. Stone, Delayed development of symptomatic improvement by (−)-deprenyl in Parkinson's disease Journal of the Neurological Sciences. ,vol. 134, pp. 143- 145 ,(1995) , 10.1016/0022-510X(95)00240-1